+208.7%
NRG vs GSK
+47.2%
+161.5%
-40.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.6% | 0.0% | +1.6% | +1.6% |
| 7D | -4.7% | -3.5% | -1.1% | -4.7% |
| 30D | -6.0% | -3.4% | -2.5% | -6.0% |
| 3M | -8.0% | -8.1% | +0.2% | -7.9% |
| 6M | -23.2% | -11.1% | -12.0% | -23.1% |
| YTD | -28.1% | +0.7% | -28.8% | -27.6% |
| 1Y | -27.3% | +20.1% | -47.4% | -26.8% |
| 3Y | +208.7% | +46.1% | +162.5% | +210.3% |
| All | +208.7% | +47.2% | +161.5% | +210.3% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling